Cannabis Report
Home > Boards > US Listed > Medical - Drugs >

Abbvie (ABBV)

ABBV RSS Feed
Add ABBV Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 6/5/2018 9:06:40 AM - Followers: 47 - Board type: Free - Posts Today: 0
Cannabis Report
ABBV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ABBV News: AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia... 06/15/2018 02:45:00 AM
ABBV News: AbbVie Declares Quarterly Dividend 06/14/2018 06:52:00 PM
ABBV News: AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual Europe... 06/12/2018 06:38:00 PM
ABBV News: AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Trea... 06/08/2018 02:55:00 PM
ABBV News: Diversity Leads to Growth in Flourishing Cannabinoid Industries 06/07/2018 08:45:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#364   Upadacitinib monotherapy bests methotrexate in RA phase-3: DewDiligence 06/05/18 09:06:40 AM
#363   ABBV “Dutch auction” tender for $7.5B of stock—price DewDiligence 05/01/18 01:47:44 PM
#362   Why this stock went up? Q1 Earnings, joanne4trade 04/26/18 11:08:52 AM
#361   ABBV raises 2018 HCV sales guidance to $3.5B DewDiligence 04/26/18 09:12:56 AM
#360   ABBV reports $919M of 1Q18 HCV sales: #msg-140323816. DewDiligence 04/26/18 08:39:48 AM
#357   Long ABBV for many reasons! We see plenty FFreedom414 04/12/18 02:09:44 PM
#356   Housekeeping note: I'm removing #msg-135739668 from a yellow-sticky DewDiligence 04/09/18 11:03:42 AM
#355   ABBV’s JAK1, Upadacitinib, bests Humira in RA phase-3: DewDiligence 04/09/18 11:02:15 AM
#354   ABBV settles Humira-patent litigation with Samsung: #msg-139804103. DewDiligence 04/05/18 10:13:37 AM
#353   AbbVie Inc $ABBV Tests Its 200-Day Moving Average, ITMS 03/28/18 11:16:05 AM
#352   Rova-T fails in third-line SCLC: DewDiligence 03/22/18 10:48:03 AM
#351   Mavyret’s market share grows in week ending 2/23/18: #msg-138970464. DewDiligence 03/02/18 11:27:21 AM
#350   Phase-3 trials of Elagolix hit all endpoints in DewDiligence 02/21/18 08:21:01 AM
#349   Mavyret scripts continue ramp-up: #msg-138602647. DewDiligence 02/17/18 12:25:14 PM
#348   At the current share price, the new annualized DewDiligence 02/17/18 12:24:08 PM
#347   NORTH CHICAGO, Ill., Feb. 15, 2018 /PRNewswire/ -- fuzzy 02/15/18 02:29:47 PM
#346   Mavyret’s US scripts (week ending 1/26/18): #msg-138221694. DewDiligence 02/02/18 08:26:55 AM
#344   ABBV 4Q17 CC notes re Mavyret/HCV market: #msg-138017796. DewDiligence 01/26/18 11:30:06 AM
#343   4Q17 HCV sales—(i.e. Mavyret)—were $510M, blowing past consensus estimates. DewDiligence 01/26/18 09:13:06 AM
#342   ABBV 4Q17 results: DewDiligence 01/26/18 09:11:47 AM
#341   AbbVie Inc. ABBV, +3.98% shares rose nearly 3% fuzzy 01/26/18 08:47:42 AM
#340   ABBV JPM slides: DewDiligence 01/10/18 12:45:04 PM
#339   Positive phase-3 for Venclexta in rrCLL: #msg-136827751. DewDiligence 12/12/17 10:51:29 AM
#338   ABBV DAY CCI STO 5,1 TREND1 11/22/17 02:09:11 PM
#337   PE Ratio = 25.90 TREND1 11/22/17 02:06:36 PM
#336   Earnings Per Share (EPS) = $ 3.65 TREND1 11/22/17 02:04:20 PM
#335   Profit/Loss = US$ 150.72B TREND1 11/22/17 02:03:18 PM
#334   ABBV buy 92.62 stocktrademan 11/06/17 12:26:43 PM
#333   Transcript of ABBV 3Q17 CC: DewDiligence 10/30/17 11:38:47 AM
#332   ABBV slide set (70 pages) on long-term outlook: DewDiligence 10/27/17 08:41:06 AM
#331   ABBV 3Q17 results: DewDiligence 10/27/17 08:40:55 AM
#330   ABBV places bet on “I-N” for AD: #msg-135656625. DewDiligence 10/24/17 02:26:26 PM
#329   Oh, I fully agree with you that all KarinCA 10/18/17 02:11:00 PM
#328   For now, I stand by the assertion in DewDiligence 10/18/17 02:06:44 PM
#327   True enough... but, it's still interesting to watch. KarinCA 10/18/17 01:52:29 PM
#326   The 2018 formularies for such PBMs as CVS DewDiligence 10/18/17 01:49:44 PM
#325   Was CVS’s Formulary Exclusion of Mavyret a Violation KarinCA 10/18/17 01:45:52 PM
#324   Positive phase-2b data for Upadacitinib in atopic dermatitis: #msg-134452680. DewDiligence 09/07/17 03:01:49 PM
#323   USPTO denies CHRS’ IPR on ABBV’s ‘619 patent: #msg-134452711. DewDiligence 09/07/17 03:00:58 PM
#321   FDA approves ABBV/ENTA’s Mavyret: #msg-133548596. DewDiligence 08/03/17 03:25:20 PM
#320   ABBV 2Q17 CC (edited) transcript: DewDiligence 07/29/17 09:46:51 AM
#319   European Commission approves GILD’s Vosevi and ABBV/ENTA’s Maviret, DewDiligence 07/28/17 12:15:23 PM
#317   https://www.wsj.com/articles/abbvie-ordered-to-pay-150-million-in-androgel-lawsuit-1500934708?mg=pro north40000 07/24/17 10:04:05 PM
#316   CHMP approves ABBV/ENTA’s Maviret (G/P) for HCV genotypes 1-6: DewDiligence 06/23/17 09:44:48 AM
#315   ABBV’s Upadacitinib—(f/k/a ABT-494)—JAK inhibitor succeeds in RA phase-3: DewDiligence 06/07/17 09:41:35 AM
#314   Transcript of ABBV’s !Q17 CC: DewDiligence 05/03/17 05:47:55 PM
#313   $ABBV - How AbbVie's 2020 Strategy Parallels Celgene's KarinCA 05/03/17 05:35:29 PM
#312   Totally agree, and well stocked with shares and options. stockspirit 04/28/17 01:24:19 PM
#311   Nice Hits, this one ready to bounce? PENNYMACHINE 04/28/17 01:17:37 PM
#310   The ruling is a positive for MNTA and DewDiligence 03/07/17 02:42:47 PM
PostSubject